These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 36299182)

  • 21. Immunotherapy for hepatocellular carcinoma.
    Li S; Yang F; Ren X
    Drug Discov Ther; 2015 Oct; 9(5):363-71. PubMed ID: 26632545
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Drug delivery system targeting advanced hepatocellular carcinoma: Current and future.
    Zhang X; Ng HLH; Lu A; Lin C; Zhou L; Lin G; Zhang Y; Yang Z; Zhang H
    Nanomedicine; 2016 May; 12(4):853-869. PubMed ID: 26772424
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
    Xing R; Gao J; Cui Q; Wang Q
    Front Immunol; 2021; 12():783236. PubMed ID: 34899747
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Systemic therapy for advanced hepatocellular carcinoma: targeted therapies.
    Tella SH; Kommalapati A; Mahipal A
    Chin Clin Oncol; 2021 Feb; 10(1):10. PubMed ID: 32434345
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Systemic Therapy for Advanced Hepatocellular Carcinoma in an Evolving Landscape.
    Mody K; Abou-Alfa GK
    Curr Treat Options Oncol; 2019 Jan; 20(2):3. PubMed ID: 30635732
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Systemic therapy for advanced hepatocellular carcinoma: past, present, and future.
    Giglia JL; Antonia SJ; Berk LB; Bruno S; Dessureault S; Finkelstein SE
    Cancer Control; 2010 Apr; 17(2):120-9. PubMed ID: 20404795
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New Therapeutic Options for Advanced Hepatocellular Carcinoma.
    Ma YS; Liu JB; Wu TM; Fu D
    Cancer Control; 2020; 27(3):1073274820945975. PubMed ID: 32799550
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Systemic Therapy for Hepatocellular Carcinoma: Advances and Hopes.
    Zhang CH; Li M; Lin YP; Gao Q
    Curr Gene Ther; 2020; 20(2):84-99. PubMed ID: 32600231
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Changing role of histopathology in the diagnosis and management of hepatocellular carcinoma.
    Rastogi A
    World J Gastroenterol; 2018 Sep; 24(35):4000-4013. PubMed ID: 30254404
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evolution of Systemic Therapy in Advanced Hepatocellular Carcinoma.
    Bejjani A; Finn RS
    Surg Oncol Clin N Am; 2024 Jan; 33(1):73-85. PubMed ID: 37945146
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prevention of hepatocellular carcinoma: potential targets, experimental models, and clinical challenges.
    Hoshida Y; Fuchs BC; Tanabe KK
    Curr Cancer Drug Targets; 2012 Nov; 12(9):1129-59. PubMed ID: 22873223
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Emerging targeted strategies in advanced hepatocellular carcinoma.
    Finn RS
    Semin Liver Dis; 2013 Feb; 33 Suppl 1():S11-9. PubMed ID: 23457035
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Selective Inhibitor of the c-Met Receptor Tyrosine Kinase in Advanced Hepatocellular Carcinoma: No Beneficial Effect With the Use of Tivantinib?
    Zhao S; Wu W; Jiang H; Ma L; Pan C; Jin C; Mo J; Wang L; Wang K
    Front Immunol; 2021; 12():731527. PubMed ID: 34804015
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular targeted therapy in hepatocellular carcinoma: from biology to clinical practice and future.
    Patel A; Sun W
    Curr Treat Options Oncol; 2014 Sep; 15(3):380-94. PubMed ID: 24838298
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Therapeutic options for intermediate-advanced hepatocellular carcinoma.
    Zhang ZM; Guo JX; Zhang ZC; Jiang N; Zhang ZY; Pan LJ
    World J Gastroenterol; 2011 Apr; 17(13):1685-9. PubMed ID: 21483627
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Implications of biomarkers in human hepatocellular carcinoma pathogenesis and therapy.
    Han LL; Lv Y; Guo H; Ruan ZP; Nan KJ
    World J Gastroenterol; 2014 Aug; 20(30):10249-61. PubMed ID: 25132742
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Single administration of Selective Internal Radiation Therapy versus continuous treatment with sorafeNIB in locally advanced hepatocellular carcinoma (SIRveNIB): study protocol for a phase iii randomized controlled trial.
    Gandhi M; Choo SP; Thng CH; Tan SB; Low AS; Cheow PC; Goh AS; Tay KH; Lo RH; Goh BK; Wong JS; Ng DC; Soo KC; Liew WM; Chow PK;
    BMC Cancer; 2016 Nov; 16(1):856. PubMed ID: 27821083
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Actionable gene expression-based patient stratification for molecular targeted therapy in hepatocellular carcinoma.
    Kwon JH; Lee N; Park JY; Yu YS; Kim JP; Shin JH; Kim DS; Joh JW; Kim DS; Choi KY; Kang KJ; Kim G; Moon YH; Wang HJ
    PLoS One; 2013; 8(6):e64260. PubMed ID: 23785399
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Current Standard and Future Perspectives in Non-Surgical Therapy for Hepatocellular Carcinoma.
    Eggert T; Greten TF
    Digestion; 2017; 96(1):1-4. PubMed ID: 28605745
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Treatment of the advanced HCC: A second revolution by using immunotherapy].
    Fartoux L; Rosmorduc O
    Biol Aujourdhui; 2018; 212(3-4):85-87. PubMed ID: 30973137
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.